It’s been a long time coming, but we may soon see the first FDA-approved NASH treatment. While no one has denied the commercial potential for effective therapies in this space,
clinical failures and false starts have fostered skepticism amongst Pharma and investors. With a bona fide success story approaching the horizon, does industry need to rethink its position on NASH and other fibrosis-related indications?

Joel Sandler sat down for a Q&A with our resident NASH expert David Lomb for an honest and actionable take on the situation playing out in NASH.

Read the full interview summary

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
This field is for validation purposes and should be left unchanged.